Biophysical Society Thematic Meeting

Biophysics in the Understanding, Diagnosis, and Treatment of Infectious Diseases Poster Abstracts

14-POS

Board 14

Blood Levels of 8-Isoprostane F2 Alpha in Chronic Hepatitis C

Soad Eltabakh

, Fathalla Ismael, Hanan Abdelaziz, Hala Maged, Rasha Ghazala.

Alexandria University, Alexandria, Egypt.

BACKGROUND/PURPOSE: The mechanism by which HCV causes liver damage is mediated

through immunological means, direct viral toxicity and induction of oxidation stress (OS) . 8-

Isoprostane F2 Alpha (8-Isop) is an important marker to assess the OS in vivo and used as

extensively to qualify lipid peroxidation. The purpose of the study was to determine the relation

of 8-Isop to the severity of HCV related liver diseases. METHODS: Fifty subjects were

evaluated and divided into 5 groups, 10 in each group : G1 : Chronic hepatitis C without

cirrhosis. G2 : Chronic hepatitis C with child A cirrhosis. G3 : Chronic hepatitis C with child B

cirrhosis. G4 : Chronic hepatitis C with child C cirrhosis. G5 : Volunteers with no evidence or

history of liver disease .All subjected to : determination of 8-Isop and lipid profile. RESULTS:

Statistical comparison between the mean value of 8-Isop in the studied groups using the F test

showed significant increase in groups 2, 3, and 4 than in G5. Also there was significant increase

of 8-Isop in G1 than G2, and in G2 than G3, also, in G3 than G4. On the other hand, there was

significant association between the severity of HCV liver disease and low cholesterol, TG, LDL,

and VLDL. COCLUSION: This results highlight the importance of OS , marked by 8-Isop in the

pathogenesis and severity of HCV related liver disease. Also, the findings reported the

importance of lipid profile parameters and its relation to disease severity. Further studies are

needed entailing the association between lipid levels, liver histo-pathological characters, and

virological parameters to predict the response to the therapy. Reference: Spengler U, Nattermann

J. Immunopathogenesis in hepatitis C virus cirrhosis.Clin Sic (London) 2007; 112(3):141-155.